Oppenheimer Reiterates Outperform on Perspective Therapeutics, Adjusts Target to $19 from $2 (10-1 reverse stock split)
Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform, Adjusts Target to $19 from $2 (10-1 reverse stock split)